SHORT MINI-FUTURE - GENMAB | Delayed Deutsche Boerse AG 13:52:18 2024-05-27 EDT | ||
| 29.22 EUR | -0.71% |
|
| Current month | -0.98% | ||
| 1 month | -0.10% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-27 | 29.22 | -0.71% |
| 24-05-24 | 29.43 | +3.59% |
| 24-05-23 | 28.41 | +1.79% |
| 24-05-22 | 27.91 | -2.38% |
| 24-05-21 | 28.59 | +1.71% |
Delayed Quote Deutsche Boerse AG
Last update May 27, 2024 at 01:52 pm
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VV9GS4 |
| ISIN | DE000VV9GS42 |
| Date issued | 2022-11-10 |
| Strike | 4,150 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 15.59 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 31.1 € |
|---|---|
| Lowest since issue | 11.51 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,955
DKK
Average target price
2,466
DKK
Spread / Average Target
+26.13%
- Stock Market
- Certificates
- Certificat
